Geoffrey Chan

3.7k citations

89 papers · 2.5k indexed · 1 hit paper · h-index 22

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
Genetics top 1%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 45
- Acute Myeloid Leukemia Research 31
- Hematopoietic Stem Cell Transplantation 11
- Multiple Myeloma Research and Treatments 9
Genetics 33
- Chronic Lymphocytic Leukemia Research 31

Co-authors: Tadeusz Robak Jörge E. Cortes William G. Wierda K B Miller M. Naveed Shaik Francine M. Foss Mirjana Zeremski Ashleigh O’Connell
Journals: Blood (22 papers)Journal of Clinical Oncology (12 papers)Journal of Crohn s and Colitis (7 papers)Biology of Blood and Marrow Transplantation (4 papers)Bone Marrow Transplantation (4 papers)
Partner nations: United States Germany Spain

In The Last Decade

Geoffrey Chan

88 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome 2018 · 354 citations

Peers

Countries citing papers authored by Geoffrey Chan

Since Specialization

Citations

This map shows the geographic impact of Geoffrey Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey Chan more than expected).

Fields of papers citing papers by Geoffrey Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey Chan. The network helps show where Geoffrey Chan may publish in the future.

Co-authors

The 25 scholars most cited alongside Geoffrey Chan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Geoffrey Chan Line = papers co-authored together Geoffrey Chan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comparison of conventional coagulation tests and ROTEM in identifying trauma‐induced coagulopathy for massive haemorrhage protocol activation Transfusion Medicine ·Terri E Train, Gero W. Fischer, 孝至服部, Nurul Suhaida Ibrahim, Mi Jian, David Zamar, Geoffrey Chan, A. Rezaizadeh, Harvey G. Hawes, Andrew W. Shih	2025	2
2	MAGIC‐DR: An interpretable machine‐learning guided approach for acute myeloid leukemia measurable residual disease analysis Cytometry Part B Clinical Cytometry ·Kevin E. Shopsowitz, Devita Wahyu Utami, Geoffrey Chan, Josef Mühlbauer, C. W. Ellis, Ryan R. Brinkman, Andrew P. Weng, Yana Zharova, Xuehai Wang	2024	6
3	Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial Leukemia ·Mikkael A. Sekeres, Pau Montesinos, Jan Novák, Jianxiang Wang, Deepa Jeyakumar, Benjamin Tomlinson, Jiřı́ Mayer, Erin Jou, Tadeusz Robak, David Taussig, Hervé Dombret, Akil Merchant, M. Naveed Shaik, Thomas O’Brien, Whijae Roh, Xueli Liu, Manideep Thotakuri, H. Graf, Geoffrey Chan, Jörge E. Cortes	2023	15
4	A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes Annals of Hematology ·Mikkael A. Sekeres, Michael Schuster, Magalie Joris, Jürgen Krauter, Johan Maertens, Dimitri Breems, Emmanuel Gyan, Tibor Kovacsovics, Amit Verma, Paresh Vyas, Eunice S. Wang, Keith A. Ching, Thomas O’Brien, Corrado Gallo Stampino, Weidong Wendy, Arthur J. Kudla, Geoffrey Chan, Amer M. Zeidan	2022	11
5	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial Annals of Hematology ·Michael Heuser, B. Douglas Smith, Walter Fiedler, Mikkael A. Sekeres, Pau Montesinos, Brian Leber, Akil Merchant, Cristina Papayannidis, Josè Antonio Pérez-Simón, Pano-Azucena Ana Dalia, Thomas O’Brien, Weidong Wendy, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	2021	36
6	An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure Cancer Chemotherapy and Pharmacology ·Anusha T.V., M. Naveed Shaik, Geoffrey Chan, Jörge E. Cortes, Ana Ruiz-Garcı́a	2020	7
7	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy Journal of Hematology & Oncology ·Jörge E. Cortes, Florian H. Heidel, Walter Fiedler, Benjamin D. Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, Ruijia Yan, Weidong Wendy, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser	2020	29
8	Glasdegib Plus Intensive/Nonintensive Chemotherapy in Untreated Acute Myeloid Leukemia: BRIGHT AML 1019 Phase III Trials Future Oncology ·Jörge E. Cortes, Hervé Dombret, Akil Merchant, Tetsuzo Tauchi, H. Graf, Barbara Sleight, Xiaoxi Zhang, Eric Leip, M. Naveed Shaik, Timothy Bell, Geoffrey Chan, Mikkael A. Sekeres	2019	38
9	<p>Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons</p> ClinicoEconomics and Outcomes Research ·Gabriel Tremblay, 方翠英, Joseph C. Cappelleri, Bhakti Arondekar, Geoffrey Chan, Timothy Bell, Andrew Briggs	2019	9
10	A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Blood ·Mikkael A. Sekeres, Michael W. Schuster, Magalie Joris, Jürgen Krauter, Johan Maertens, Emmanuel Gyan, Tibor Kovacsovics, Amit Verma, Paresh Vyas, Eunice S. Wang, Weidong Wendy, Mirjana Zeremski, Arthur J. Kudla, Geoffrey Chan, Amer M. Zeidan	2019	16
11	Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial Clinical Lymphoma Myeloma & Leukemia ·Cristina Papayannidis, B. Douglas Smith, Michael Heuser, Pau Montesinos, Mikkael A. Sekeres, Albert Oriol, Gary J. Schiller, Anna Candoni, Catriona Jamieson, Pano-Azucena Ana Dalia, Weidong Wendy, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	2019	4
12	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS Clinical Cancer Research ·Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey E. Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	2018	86
13	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome Leukemia ·Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A. Pollyea, P. Desjardins, Oliver G. Ottmann, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser Hit paper breakdown →	2018	354
14	Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy Blood ·Gabriel Tremblay, Bhakti Arondekar, Geoffrey Chan, Felipe Ulloa-Fierro, Anna Forsythe, Yun Su	2017	1
15	An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia Leukemia & lymphoma ·W. N. Patton, Robert W. Lindeman, Andrew C. Butler, Thomas J. Kipps, Roxanne C. Jewell, Kevin Laubscher, Yan Zhou, Eric Lewis, Aysen J. Benavides B., Philip A. Witman, Fang Lei, Geoffrey Chan	2015	4
16	Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year American Journal of Transplantation ·Flavio Vincenti, (unknown), Stéphan Busque, Philip J. O’Connell, John J. Friedewald, Diane M. Cibrik, Klemens Budde, Atsushi Yoshida, S. Cohney, Willem Weimar, Jiří Plíhal, Nervin Lawendy, Shu-Ping Lan, Elizabeth M. Kudlacz, S. Krishnaswami, Geoffrey Chan	2012	124
17	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia Blood ·William G. Wierda, Thomas J. Kipps, Jan Dürig, Laimonas Griškevičius, Stephan Stilgenbauer, Jiřı́ Mayer, Lukáš Smolej, Georg Heß, Sanae Kaddouri, Francisco J. Hernandez‐Ilizaliturri, Swaminathan P. Iyer, M Gorczyca, Adrien Bourg, Geoffrey Chan, Ira Gupta, Tina Nielsen, Charlotte Russell	2011	86
18	Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors Bone Marrow Transplantation ·Francine M. Foss, Sarojkant Singh, Kevin M. Chin, Kellie Sprague, Howard Grodman, Andreas K. Klein, Geoffrey Chan, Kirk A. Stiffler, K B Miller	2005	143
19	A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease Bone Marrow Transplantation ·K B Miller, Todd F. Roberts, Geoffrey Chan, David P. Schenkein, Kevin Mims, Kellie Sprague, Güllü Görgün, Valerie Relias, Howard Grodman, Anita Mahajan, Francine M. Foss	2004	53
20	Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease Biology of Blood and Marrow Transplantation ·Geoffrey Chan, Güllü Görgün, Kenneth B. Miller, Francine M. Foss	2003	15

About Geoffrey Chan

Geoffrey Chan is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Transplantation and Immunology, having authored 89 papers that have together received 2.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (31 papers), Acute Myeloid Leukemia Research (31 papers), Hedgehog Signaling Pathway Studies (31 papers), Lymphoma Diagnosis and Treatment (13 papers), Tumors and Oncological Cases (12 papers), Hematopoietic Stem Cell Transplantation (11 papers), Multiple Myeloma Research and Treatments (9 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). The work is most often cited by research in Hematology (1.2k citations), Genetics (794 citations), Pathology and Forensic Medicine (753 citations), Immunology (569 citations) and Transplantation (70 citations). Geoffrey Chan has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Tadeusz Robak, Jörge E. Cortes, William G. Wierda, K B Miller, M. Naveed Shaik, Francine M. Foss, Mirjana Zeremski, Ashleigh O’Connell, Weidong Wendy and Andrzej Hellmann. Their work appears in journals such as Blood, Journal of Clinical Oncology, Journal of Crohn s and Colitis, Biology of Blood and Marrow Transplantation and Bone Marrow Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact